ABOSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Acumen Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.77+0.08 (+4.73%)
Close on Oct 19, 2026
- Market cap
- $127.88M
- P/E (TTM)
- –
- Dividend yield
- –
Acumen Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Acumen Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $128.00M | $166.30M |
| Enterprise Value | $37.47M | $87.12M |
| PB Ratio | 2.24 | 2.03 |
| P/TBV Ratio | 2.24 | 2.31 |
Income (trailing twelve months)
| Measure | Acumen Pharmaceuticals | Industry median |
|---|---|---|
| Operating Income | -$105.42M | -$21.49M |
| Net Income | -$105.04M | -$22.46M |
| EBITDA | -$105.42M | -$17.14M |
| EPS (Diluted) | -$1.63 | -$0.83 |
Returns
| Measure | Acumen Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -120.5% | -53.2% |
| Return on Assets (ROA) | -73.0% | -41.0% |
| Return on Capital Employed (ROCE) | -152.4% | -38.0% |
Balance sheet
| Measure | Acumen Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $110.20M | $62.64M |
| Total Debt | $19.67M | $120.13M |
| Net Cash (Debt) | $90.53M | $15.77M |
| Net Cash Per Share | $1.25 | $0.66 |
| Equity (Book Value) | $57.26M | $48.61M |
| Book Value Per Share | $0.79 | $1.36 |
| Tangible Book Value | $57.26M | $23.01M |
| Working Capital | $68.67M | $75.09M |
Financial position
| Measure | Acumen Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 2.47 | 3.30 |
| Quick Ratio | 2.35 | 2.39 |
| Debt / Equity | 0.34 | 0.51 |
| Interest Coverage | -24.41 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Acumen Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$91.79M | -$12.39M |
| Capital Expenditures | $0 | -$1.07M |
| Free Cash Flow | -$91.79M | -$20.34M |
| FCF Per Share | -$1.27 | -$0.42 |
Efficiency
| Measure | Acumen Pharmaceuticals | Industry median |
|---|---|---|
| Profits Per Employee | -$1.72M | -$705.27K |
| Employee Count | 61 | 74 |
Dividends and yields
| Measure | Acumen Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -82.1% | -22.8% |
| FCF Yield | -71.7% | -9.02% |
Shares
| Measure | Acumen Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 72,317,300 | 58,139,000 |
| Shares Change (YoY) | 6.37% | 11.1% |
| Shares Change (QoQ) | 0.12% | 0.54% |
| Float | 35,348,200 | 49,154,900 |
| Shares Held by Insiders | 51.1% | 11.6% |
| Shares Held by Institutions | 66.2% | 59.4% |
Scores
| Measure | Acumen Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -7.01 | -0.27 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Acumen Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.